Home : FDA Drug Database : Abacavir : Newsfeeds

Abacavir - Newsfeeds

Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
Truvada should not be coadministered with Atripla, Emtriva, Viread or lamivudine-containing products, including Combivir(R) (lamivudine/zidovudine), Epivir(R) or Epivir-HBV(R) (lamivudine), Epzicom(R) (abacavir sulfate/lamivudine) or Trizivir(R) (abacavir ...
ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI
An oral presentation described the innovative and rational design approach that led to the identification of a potent series of HIV-1 integrase inhibitors, including the lead clinical candidate, S/GSK1349572.   In vitro studies of S/GSK1349572 across a ...
OXIS introduces ErgoFlex for relief of joint pain
OXIS International, Inc. (OTC Bulletin Board: OXIS ; Euronext Paris: OXI) announces the market launch of ErgoFlex ™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS ...
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR For Abacavir Sulfate Tablets, 60 Mg
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application ...
How do data exclusivity periods affect pharmaceutical innovation?
Pharmaceutical companies and generic drug manufacturers have long been at odds over regulations about "data exclusivity," the period of time before generic manufacturers can make use of valuable clinical trial data. A new study in the January 2011 issue of ...
Liver Disease A Possible Predictor Of Stroke
People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre. The study is the first to ...
ZOVIRAX CAPSULES
May give with food. Genital herpes: Initially 200mg every 4 hrs (5 times daily) for 10 days. Chronic: 400mg 2 times daily or 200mg 3–5 times daily for up to 12 months, then reevaluate. Intermittent: (at 1 st sign of recurrence) 200mg every 4 hrs (5 times ...
ZOVIRAX SUSPENSION
Acyclovir 200mg/5mL; banana flavor. May give with food. Genital herpes: Initially 200mg every 4 hrs (5 times daily) for 10 days. Chronic: 400mg 2 times daily or 200mg 3–5 times daily for up to 12 months, then reevaluate. Intermittent: (at 1 st sign of ...
HIV Drug Combos Not Equal at High Viral Loads
In patients with a high HIV viral load at the start of initial therapy, regimens based on tenofovir/emtricitabine (Truvada) were more effective than those based on abacavir/lamivudine (Epzicom), researchers said. The surprise finding led to a premature ...
Gilead Sciences Submits European Marketing Application For Once-Daily Single-Tablet Regimen Of ...
... once-daily efavirenz (600 mg) combined with an investigator-selected background regimen consisting of two nucleoside reverse transcriptase inhibitors (abacavir and lamivudine, or emtricitabine and tenofovir ...
Gilead's Single-Tablet “Quad” HIV Regimen Maintains High Viral Suppression Through 48 Weeks ...
including Combivir® (lamivudine/zidovudine), Epivir® or Epivir-HBV® (lamivudine), Epzicom® (abacavir sulfate/lamivudine) or Trizivir® (abacavir sulfate/lamivudine/zidovudine). In treatment-experienced patients,
Switch From Abacavir to Tenofovir Improves Cholesterol Levels
People on a regimen containing abacavir saw their cholesterol drop quickly and significantly when they switched to a similar regimen containing tenofovir. What’s more, people who switched expressed greater ...
AIDS Drug Combinations Given to Pregnant Women Block 99 Percent of HIV Transmission to Breastfed ...
Similar results were found for all treatment groups, including 560 women who were randomized to receive either zidovudine, lamivudine, and abacavir (co-formulated as Trizivir) or zidovudine, lamivudine, lopinivir ...
Two Forms of HAART Highly Effective in Trial of Pregnant HIV Positive Women in Botswana
Some previous studies had found that the lamivudine, zidovudine and abacavir (a three nucleoside reverse transcriptase inhibitor combination) to be less effective than other forms of HAART. This study wasn't powered to ...
GSK drops drug prices for poor nations
... A fund of a further £10-million (R130-million) to support a public-private partnership into research and development of new paediatric ARVs; An extension of a voluntary licensing policy to include the second-line ARV abacavir on a royalty-free ...
GSK waives patent restraint on HIV drugs
The new pledges for the first time expand the waiver on rights to Abacavir, and he stressed they also applied to supplies to low-income countries outside Africa provided the generic manufacturers could meet the criteria of “quality, capacity and ...
GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa ...
GSK will extend its existing Voluntary Licensing Policy to include abacavir - A new voluntary licence has been agreed, on a non-exclusive basis, with South Africa based Aspen Pharmacare Ltd for the manufacture of abacavir. GSK will not charge ...
DART Study: Laboratory Monitoring Not Required for Safe HAART Delivery
The remaining patients received either zidovudine/lamivudine plus nevirapine or zidovudine/lamivudine plus abacavir. After approximately 5 years of follow-up, 87% of the clinical-monitoring group and 90% of the laboratory-monitoring group were ...
AIDS Drug Slows Spread of Deadly Childhood Brain Cancer
A study published in the current issue of the International Journal of Cancer reports that ABC (Abacavir) suppresses the enzyme telomerase. Telomerase activity appears to be essential for certain tumor survival and growth, such as medulloblastoma -- a ...
Want to contact a District of Columbia Abacavir lawyer? ...Get a free case evaluation from one of our District of Columbia Abacavir lawyers now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Need An Abacavir Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Want to contact a District of Columbia Abacavir lawyer? ...Get a free case evaluation from one of our District of Columbia Abacavir lawyers now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Abacavir Case - Submit Your Information Below

Do you need legal assistance with your Abacavir case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * FDA Drug Database: Abacavir Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.